“Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks”
September 4, 2024
“…COMPASS Pathways (CMPS)… Morgan Stanley analyst Vikram Purohit, who covers the stock, sees CMPS as presenting a compelling risk-reward opportunity. He highlights the company’s leading clinical program… To this end, Purohit rates CMPS shares an Overweight (i.e. Buy), and his $23 price target points toward a robust one-year upside potential of ~220%…
Rocket Pharmaceuticals (RCKT)… Ulz complements his Overweight (i.e. Buy) rating on RCKT with a $45 price target, implying a 142% gain for the stock in the coming 12 months… No one is arguing with that take on Wall Street. The stock’s Strong Buy consensus rating is based on Buy recommendations only – 8, in total. The forecast calls for one-year gains of ~147%, considering the average price target stands at $45.86…”